Therapy with Antibody to Tumor Necrosis Factor in Sepsis
Recent data indicate that proinflammatory cytokines mediate pathophysiological events during clinical sepsis. The cytokine tumor necrosis factor (TNF) has been closely associated with adverse outcome from sepsis, both in animal models and in the clinical setting. Accordingly, monoclonal antibodies w...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1993-11, Vol.17 (Supplement-2), p.S515-S519 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S519 |
|---|---|
| container_issue | Supplement-2 |
| container_start_page | S515 |
| container_title | Clinical infectious diseases |
| container_volume | 17 |
| creator | PENNINGTON, J. E |
| description | Recent data indicate that proinflammatory cytokines mediate pathophysiological events during clinical sepsis. The cytokine tumor necrosis factor (TNF) has been closely associated with adverse outcome from sepsis, both in animal models and in the clinical setting. Accordingly, monoclonal antibodies with the capacity to neutralize TNF in vitro have been developed for evaluation as therapeutic agents in clinical sepsis. Preclinical studies in animal models of sepsis due to gram-negative as well as to gram-positive bacteria suggest that monoclonal antibodies to TNF may have potential as a therapeutic agent. Clinical trials to test this hypothesis are under way. |
| doi_str_mv | 10.1093/clinids/17.Supplement_2.S515 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_76131842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4457436</jstor_id><sourcerecordid>4457436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-242a3f93a494cb582b61ce81e160c9999df618abca3c777395727883d3234f0f3</originalsourceid><addsrcrecordid>eNpNkFtr3DAQRkVJyK39By34IeTNG41HsmTISwhN0hJa6LoQ-iJkWSZKfKtkk-y_j5Y1S_Siy_lmNBxCzoGugBZ4aVrXuzpcglit53FsbWf7SWWrNQf-iZwAR5HmvICDeKZcpkyiPCanITxTCiApPyJHMhMsB3lCZPlkvR43yaubnpLrfnLVUG-SaUjKuRt88ssaPwQXklttpnh3fbK2Y3z4TA4b3Qb7ZdnPyN_b7-XNffrw--7HzfVDahjNpzRjmcamQM0KZiousyoHYyVYyKkp4qqbOIeujEYjhMCCi0xIiTVmyBra4Bm52PUd_fB_tmFSnQvGtq3u7TAHJXJAkCyLwatdcDtw8LZRo3ed9hsFVG3FqUWcAqE-ilNbcbH82_LPXHW23hcvpiI_X7gORreN171xYR_D6JWxbezrLvYcoq49ZowLhnnE6Q67MNm3Pdb-ReUCBVf3j__U-ieWUP55VBzfAcVolIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76131842</pqid></control><display><type>article</type><title>Therapy with Antibody to Tumor Necrosis Factor in Sepsis</title><source>MEDLINE</source><source>Oxford Journals A-Z Collection</source><source>JSTOR</source><creator>PENNINGTON, J. E</creator><creatorcontrib>PENNINGTON, J. E</creatorcontrib><description>Recent data indicate that proinflammatory cytokines mediate pathophysiological events during clinical sepsis. The cytokine tumor necrosis factor (TNF) has been closely associated with adverse outcome from sepsis, both in animal models and in the clinical setting. Accordingly, monoclonal antibodies with the capacity to neutralize TNF in vitro have been developed for evaluation as therapeutic agents in clinical sepsis. Preclinical studies in animal models of sepsis due to gram-negative as well as to gram-positive bacteria suggest that monoclonal antibodies to TNF may have potential as a therapeutic agent. Clinical trials to test this hypothesis are under way.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/clinids/17.Supplement_2.S515</identifier><identifier>PMID: 8274618</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Animal models ; Animals ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies ; Antibodies - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Disease Models, Animal ; Endotoxins ; Humans ; Infections ; Management of Sepsis ; Medical sciences ; Mice ; Monoclonal antibodies ; Mortality ; Papio ; Pharmacology. Drug treatments ; Sepsis ; Septic shock ; Shock, Septic - therapy ; Survival Analysis ; Tumor Necrosis Factor-alpha - analysis ; Tumor Necrosis Factor-alpha - immunology ; Tumor necrosis factors</subject><ispartof>Clinical infectious diseases, 1993-11, Vol.17 (Supplement-2), p.S515-S519</ispartof><rights>Copyright 1993 The University of Chicago</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-242a3f93a494cb582b61ce81e160c9999df618abca3c777395727883d3234f0f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4457436$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4457436$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,803,23930,23931,25140,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3805448$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8274618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PENNINGTON, J. E</creatorcontrib><title>Therapy with Antibody to Tumor Necrosis Factor in Sepsis</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Recent data indicate that proinflammatory cytokines mediate pathophysiological events during clinical sepsis. The cytokine tumor necrosis factor (TNF) has been closely associated with adverse outcome from sepsis, both in animal models and in the clinical setting. Accordingly, monoclonal antibodies with the capacity to neutralize TNF in vitro have been developed for evaluation as therapeutic agents in clinical sepsis. Preclinical studies in animal models of sepsis due to gram-negative as well as to gram-positive bacteria suggest that monoclonal antibodies to TNF may have potential as a therapeutic agent. Clinical trials to test this hypothesis are under way.</description><subject>Animal models</subject><subject>Animals</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies</subject><subject>Antibodies - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Endotoxins</subject><subject>Humans</subject><subject>Infections</subject><subject>Management of Sepsis</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Papio</subject><subject>Pharmacology. Drug treatments</subject><subject>Sepsis</subject><subject>Septic shock</subject><subject>Shock, Septic - therapy</subject><subject>Survival Analysis</subject><subject>Tumor Necrosis Factor-alpha - analysis</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>Tumor necrosis factors</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkFtr3DAQRkVJyK39By34IeTNG41HsmTISwhN0hJa6LoQ-iJkWSZKfKtkk-y_j5Y1S_Siy_lmNBxCzoGugBZ4aVrXuzpcglit53FsbWf7SWWrNQf-iZwAR5HmvICDeKZcpkyiPCanITxTCiApPyJHMhMsB3lCZPlkvR43yaubnpLrfnLVUG-SaUjKuRt88ssaPwQXklttpnh3fbK2Y3z4TA4b3Qb7ZdnPyN_b7-XNffrw--7HzfVDahjNpzRjmcamQM0KZiousyoHYyVYyKkp4qqbOIeujEYjhMCCi0xIiTVmyBra4Bm52PUd_fB_tmFSnQvGtq3u7TAHJXJAkCyLwatdcDtw8LZRo3ed9hsFVG3FqUWcAqE-ilNbcbH82_LPXHW23hcvpiI_X7gORreN171xYR_D6JWxbezrLvYcoq49ZowLhnnE6Q67MNm3Pdb-ReUCBVf3j__U-ieWUP55VBzfAcVolIA</recordid><startdate>19931101</startdate><enddate>19931101</enddate><creator>PENNINGTON, J. E</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19931101</creationdate><title>Therapy with Antibody to Tumor Necrosis Factor in Sepsis</title><author>PENNINGTON, J. E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-242a3f93a494cb582b61ce81e160c9999df618abca3c777395727883d3234f0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies</topic><topic>Antibodies - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Endotoxins</topic><topic>Humans</topic><topic>Infections</topic><topic>Management of Sepsis</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Papio</topic><topic>Pharmacology. Drug treatments</topic><topic>Sepsis</topic><topic>Septic shock</topic><topic>Shock, Septic - therapy</topic><topic>Survival Analysis</topic><topic>Tumor Necrosis Factor-alpha - analysis</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>Tumor necrosis factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PENNINGTON, J. E</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PENNINGTON, J. E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapy with Antibody to Tumor Necrosis Factor in Sepsis</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1993-11-01</date><risdate>1993</risdate><volume>17</volume><issue>Supplement-2</issue><spage>S515</spage><epage>S519</epage><pages>S515-S519</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Recent data indicate that proinflammatory cytokines mediate pathophysiological events during clinical sepsis. The cytokine tumor necrosis factor (TNF) has been closely associated with adverse outcome from sepsis, both in animal models and in the clinical setting. Accordingly, monoclonal antibodies with the capacity to neutralize TNF in vitro have been developed for evaluation as therapeutic agents in clinical sepsis. Preclinical studies in animal models of sepsis due to gram-negative as well as to gram-positive bacteria suggest that monoclonal antibodies to TNF may have potential as a therapeutic agent. Clinical trials to test this hypothesis are under way.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>8274618</pmid><doi>10.1093/clinids/17.Supplement_2.S515</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1993-11, Vol.17 (Supplement-2), p.S515-S519 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76131842 |
| source | MEDLINE; Oxford Journals A-Z Collection; JSTOR |
| subjects | Animal models Animals Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies Antibodies - therapeutic use Antibodies, Monoclonal - therapeutic use Biological and medical sciences Disease Models, Animal Endotoxins Humans Infections Management of Sepsis Medical sciences Mice Monoclonal antibodies Mortality Papio Pharmacology. Drug treatments Sepsis Septic shock Shock, Septic - therapy Survival Analysis Tumor Necrosis Factor-alpha - analysis Tumor Necrosis Factor-alpha - immunology Tumor necrosis factors |
| title | Therapy with Antibody to Tumor Necrosis Factor in Sepsis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T15%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapy%20with%20Antibody%20to%20Tumor%20Necrosis%20Factor%20in%20Sepsis&rft.jtitle=Clinical%20infectious%20diseases&rft.au=PENNINGTON,%20J.%20E&rft.date=1993-11-01&rft.volume=17&rft.issue=Supplement-2&rft.spage=S515&rft.epage=S519&rft.pages=S515-S519&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/clinids/17.Supplement_2.S515&rft_dat=%3Cjstor_proqu%3E4457436%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76131842&rft_id=info:pmid/8274618&rft_jstor_id=4457436&rfr_iscdi=true |